XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
October 19, 2016 09:00 ET
|
XOMA Ltd.
BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s...
XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
September 15, 2016 19:26 ET
|
XOMA Ltd.
Results Demonstrate XOMA 358 Mechanism-of-Action in Rare Endocrine ConditionsCompany Plans to Advance XOMA 358 to Multi-dose Phase 2b Studies BERKELEY, Calif., Sept. 15, 2016 (GLOBE...
XOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference
August 11, 2016 14:32 ET
|
XOMA Corporation
BERKELEY, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the...
XOMA Reports Second Quarter 2016 Achievements and Financial Results
August 03, 2016 16:01 ET
|
XOMA Corporation
BERKELEY, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and...
XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism
July 20, 2016 09:00 ET
|
XOMA Corporation
XOMA 358 previously secured Orphan Drug Designation from the FDA for the treatment of Congenital Hyperinsulinism (CHI)Phase 2 clinical studies currently enrolling patients with CHI in the United...
XOMA to Present at the Cantor Fitzgerald Healthcare Conference
July 05, 2016 14:05 ET
|
XOMA Corporation
BERKELEY, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the...
InSpark Technologies Announces the Results of the Home Use and Human Factors Study of Vigilant(TM) in People with Diabetes
June 11, 2016 11:00 ET
|
InSpark Technologies
Vigilant met or exceeded all human factors criteria for safety, comprehension and ease of useEarly evidence of clinical benefit was demonstrated by a 51 percent reduction in the proportion of blood...
XOMA to Present at the Jefferies Global Healthcare Conference
June 02, 2016 13:48 ET
|
XOMA Corporation
BERKELEY, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the...
InSpark Technologies Enters into Clinical Trial Collaborations to Study the Effectiveness of Mobile Health Technology in Preventing Low Blood Sugars in People With Diabetes
May 05, 2016 08:00 ET
|
InSpark Technologies
CHARLOTTESVILLE, Va., May 05, 2016 (GLOBE NEWSWIRE) -- InSpark Technologies, Inc. announced today that it has entered into clinical study collaborations with Atlanta Diabetes Associates, a large...
XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
May 04, 2016 16:01 ET
|
XOMA Corporation
BERKELEY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational...